Acute Lymphoid Leukemia After Anti-TNF-alpha Treatment: A Case Report and Review of the Literature

被引：0
作者：
Gediz Ozdemirkiran, Fusun [1 ]
Payzin, Bahriye Kadriye [1 ]
Coban, Eyup [2 ]
Bayram, Korhan Baris [3 ]
Kucukzeybek, Betul [4 ]
机构：
[1] Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Hematol, TR-35360 Izmir, Turkey
[2] Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Internal Med, TR-35360 Izmir, Turkey
[3] Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Phys Med & Rehabil, TR-35360 Izmir, Turkey
[4] Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Pathol, TR-35360 Izmir, Turkey
来源：
ARCHIVES OF RHEUMATOLOGY | 2015年 / 30卷 / 04期
关键词：
Acute lymphoid leukemia; ankylosing spondylitis; anti-tumor necrosis factor-alpha drugs; PATIENT RECEIVING ETANERCEPT; NECROSIS-FACTOR INHIBITORS; ACUTE MYELOGENOUS LEUKEMIA; ACUTE MYELOID-LEUKEMIA; RHEUMATOID-ARTHRITIS; MALIGNANCIES; THERAPY; RISK; ADALIMUMAB; INFLIXIMAB;
D O I：
10.5606/ArchRheumatol.2015.5669
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The efficacy and safety of anti-tumor necrosis factor-alpha drugs have been shown in active ankylosing spondylitis cases that are resistant to traditional disease-modifying antirheumatic drugs. However, it is well known that these drugs may cause some complications as reactivation of tuberculosis and various hematologic malignancies. In this article, we report a 40-year-old male patient with ankylosing spondylitis who developed Philadelphia chromosome-positive acute lymphoid leukemia after treatment with tumor necrosis factor-alpha inhibitors.
引用
收藏
页码：349 / 352
页数：4
相关论文
共 21 条
  • [1] Alcaín G, 2003, AM J GASTROENTEROL, V98, P2577
  • [2] Alert F, 2009, TUMOR NECROSIS FACTO
  • [3] Haematopoietic malignancies in rheumatoid arthritis:: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
    Askling, J
    Fored, CM
    Baecklund, E
    Brandt, L
    Backlin, C
    Ekbom, A
    Sundström, C
    Bertilsson, L
    Cöster, L
    Geborek, P
    Jacobsson, LT
    Lindblad, S
    Lysholm, J
    Rantapää-Dahlqvist, S
    Saxne, T
    Klareskog, L
    Feltelius, N
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (10) : 1414 - 1420
  • [4] Risk of haematological malignancies in HLA-B27 carriers
    Au, WY
    Hawkins, BR
    Cheng, N
    Lie, AKW
    Liang, R
    Kwong, YL
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (02) : 320 - 322
  • [5] Acute myelogenous leukemia in a patient receiving etanercept for psoriasis
    Bachmeyer, Claude
    Thioliere, Brigitte
    Khosrotehrani, Kiarash
    Cattan, Elie
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (01) : 169 - 170
  • [6] Acute myelogenous leukaemia following etanercept therapy
    Bakland, G
    Nossent, H
    [J]. RHEUMATOLOGY, 2003, 42 (07) : 900 - 901
  • [7] Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
    Bongartz, T
    Sutton, AJ
    Sweeting, MJ
    Buchan, I
    Matteson, EL
    Montori, V
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19): : 2275 - 2285
  • [8] Tumor necrosis factor antagonist therapy and lymphoma development - Twenty-six cases reported to the Food and Drug Administration
    Brown, SL
    Greene, MH
    Gershon, SK
    Edwards, ET
    Braun, MM
    [J]. ARTHRITIS AND RHEUMATISM, 2002, 46 (12): : 3151 - 3158
  • [9] Acute Lymphoid Leukemia in a Crohn's Disease Patient During Treatment with Adalimumab After a Prolonged Treatment with Azathioprine and Steroids
    Cesarini, M.
    Vernia, P.
    Angelucci, E.
    [J]. INFLAMMATORY BOWEL DISEASES, 2010, 16 (03) : 371 - 372
  • [10] Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis
    Davis, J. C., Jr.
    van der Heijde, D. M.
    Braun, J.
    Dougados, M.
    Clegg, D. O.
    Kivitz, A. J.
    Fleischmann, R. M.
    Inman, R. D.
    Ni, L.
    Lin, S-L
    Tsuji, W. H.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (03) : 346 - 352
123